高剂量匹伐他汀与阿托伐他汀对代谢综合征患者致糖尿病性的长期影响比较(LESS-DM):随机对照试验研究方案
LESS-DM试验为前瞻性、随机、开放标签、活性对照临床研究,计划纳入500例代谢综合征患者,按1:1随机接受高剂量匹伐他汀(4 mg)或阿托伐他汀(20 mg)每日治疗24个月,主要终点为他汀治疗后糖化血红蛋白变化,旨在评估匹伐他汀与阿托伐他汀对糖代谢的长期影响。
要点
- LESS-DM试验比较匹伐他汀4 mg与阿托伐他汀20 mg每日治疗24个月对代谢综合征患者糖代谢的影响。
- 主要终点为糖化血红蛋白变化,次要终点包括胰岛素、C肽、HOMA-IR、HOMA-β、脂联素、颈动脉弹性指标、心功能指标及新发糖尿病和心血管疾病发生率。
- 他汀致糖尿病性仍受关注,近期研究提示匹伐他汀对致糖尿病性呈中性或有利影响,但尚无随机试验在高风险人群中比较其长期糖代谢效应。
核心结论
- 本试验将探讨匹伐他汀4 mg是否不干扰代谢综合征患者的糖代谢,并提供他汀类型依赖性致糖尿病效应的机制信息及强化他汀治疗对血管和心脏变化的替代数据。
研究设计与样本
- LESS-DM试验为前瞻性、随机、开放标签、活性对照临床研究,计划将500例代谢综合征患者按1:1随机分配接受高剂量匹伐他汀(4 mg)或阿托伐他汀(20 mg)每日治疗24个月。
主要发现
- 主要终点为他汀治疗后糖化血红蛋白的变化。
- 次要终点包括胰岛素、C肽、胰岛素抵抗稳态模型评估和胰岛素分泌稳态模型评估及脂联素等生化标志物的变化。
- 次要终点包括颈动脉弹性指标和心功能指标等影像学参数的变化。
- 次要终点包括新发糖尿病和心血管疾病等临床事件的发生率。
关键数值与推荐
- 匹伐他汀组剂量为4 mg每日,阿托伐他汀组剂量为20 mg每日,治疗时长24个月。
- 计划随机化500例代谢综合征患者,按1:1分配。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diabetogenic action of statins remains a concern, particularly in patients at high risk for diabetes receiving intensive statin therapy. Despite the risk of diabetes with statin use being considered a potential class effect, recent studies have suggested that pitavastatin exerts neutral or favorable effects on diabetogenicity. However, no randomized trial has compared the long-term effects of pitavastatin with those of other statins on glycemic control in populations at high risk for diabetes. Hence, we aim to assess the long-term effects of pitavastatin in comparison with atorvastatin on glucose metabolism in patients with metabolic syndrome (MetS). METHODS/DESIGN: The Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM) trial is a prospective, randomized, open-label, active control clinical trial of patients with MetS. We plan to randomize 500 patients with MetS (1:1) to receive high-dose pitavastatin (4 mg) or atorvastatin (20 mg) daily for 24 months. The primary endpoint will be the change in hemoglobin A1c after statin treatment. Secondary endpoints will include the following: (1) changes in biochemical markers, including insulin, C-peptide, homeostasis model assessment of insulin resistance and insulin secretion, and adiponectin; (2) changes in imaging parameters, including carotid elasticity metrics and indices of cardiac function; and (3) the incidence of clinical events, including new-onset diabetes and cardiovascular disease. DISCUSSION: In this trial, we will explore whether pitavastatin 4 mg does not disturb glucose metabolism in patients with MetS. It will also provide mechanistic information on statin type-dependent diabetogenic effects and surrogate data regarding vascular and cardiac changes achieved by intensive statin therapy. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02940366 . Registered on 19 October 2016.
引用
- Park JB, Jung JH, Yoon YE, et al. Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial. Trials. 2017. PMID: 29078817. doi:10.1186/s13063-017-2229-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。